Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q1 FY23 Earnings Presentation
28 slides from Zota Health Care's earnings presentation, Sep 17, 2022
Slide 1: Regulation 30 cover letter to NSE
September 17, 2022 To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: Investor Presentation Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Require
Slide 2: Q1FY23 Performance Highlights
Q1FY23 PERFORMANCE HIGHLIGHTS SEPTEMBER 2022
Slide 3: Safe Harbour
Safe Harbour This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer
Slide 4: Table Of Contents
Table Of Contents 01 RESULT HIGHLIGHTS 02 OPERATIONAL METRICS 03 DAVAINDIA BUSINESS OUTLOOK 04 & STRATEGY 05 FINANCIAL SUMMARY zotahealthcare.com
Slide 5: Q1FY23 - Result Highlights
Q1FY23- Result Highlights zotahealthcare.com
Slide 6: Stand Quarterly Financial Highlights
Stand Quarterly Financial Highlights Q-o-Q Revenues (₹ Lakhs) Gross Profit (%) Operating Profit (₹ Lakhs) PAT (₹ Lakhs) Q1-FY23 2,948.78 Q1-FY23 37.30% Q1-FY23 206.14 Q1-FY23 146.41 Q4-FY22 3,175.26 Q4-FY22 26.11% Q4-FY22 36.18 Q4-FY22 34.74 Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) Operating Profit
Slide 7: Revenue Break up – Quarterly
Revenue Break up – Quarterly Domestic Sales Dava India Sales Export Sales (SEZ) 1,815.1 1023.8 1019.3 766.6 1,501.1 632.6 650.4 1,162.8 896.8 Q1-FY22 Q4-FY22 Q1-FY23 Q1-FY22 Q4-FY22 Q1-FY23 Q1-FY22 Q4-FY22 Q1-FY23 06 zotahealthcare.com
Slide 8: FY Result Highlights
FY- Result Highlights zotahealthcare.com
Slide 9: Stand Profit & Loss Statement - Quarterly
Stand Profit & Loss Statement - Quarterly Particulars (Rs Lakhs) Q1FY23 Q4FY22 YoY % QoQ % Q1FY22 Export Sales (SEZ) 766.6 650.3 21% 18% 632.6 Dava India Sales 1019.3 1023.8 14% 0% 896.8 Domestic Sales 1162.8 1501.1 -36% -23% 1,815.1 Revenues from Operations 2,948.78 3,175.26 -12% -7% 3,344.49 Cost
Slide 10: Management Commentary
Management Commentary 01 The Company reported a 02 Domestic Sales reported a 03 The sales contribution from decline in Revenues in decline of 36% YoY and 23% new-age business stood at Q1FY22, primarily on account QoQ, while exports 61% in Q1FY23 as compared of lower Domestic Sales and performance co
Slide 11: Management Commentary
Management Commentary DOMESTIC OPERATIONS Domestic Revenues registered EBITDA at ₹ 180.80 PAT stood at ₹ a decline of 13.60% QoQ and Lakhs for Q1FY23. 105.24 Lakhs for 19.55% YoY at ₹ 2182.14 Lakhs Q1FY23. on account of lower dispatch due to warehouse shifting. *Domestic Operations includes the oper
Slide 12: Davaindia Generic Pharmacy
Davaindia Generic Pharmacy zotahealthcare.com
Slide 13: Davaindia Key Figures
Davaindia Key Figures Gross Mercantile Value (GMV) Total GMV of Davaindia Stores stood at 1,595 Lakhs during Q1FY23 down 7% QoQ No. of SKU’s New Stores rolled-out 1,653 1,644 59 55 1,614 51 1,585 34 Q2-FY22 Q3-FY22 Q4-FY22 Q1-FY23 Q2-FY22 Q3-FY22 Q4-FY22 Q1-FY23 12 zotahealthcare.com
Slide 14: Davaindia Key Figures
zotahealthcare.com 6,43,120 Q1-FY23 6,41,712 Q4-FY22 No. of Customers Served 5,68,183 Q3-FY22 5,40,924 Q2-FY22 4,73,181 Q1-FY22 4,40,458 Q4-FY21 3,23,395 Q3-FY21 Davaindia Key Figures 3,52,623 Q2-FY21 3,38,415 Q1-FY21 248 Q1-FY23 267 Q4-FY22 237 Q3-FY22 Average Wallet Spend 229 Q2-FY22 220 Q1-FY22 2
Slide 15: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy During the quarter Davaindia has Davaindia has led the revolution of Davaindia retail pharmacy stores’ catered to the highest-ever number of patients opting for generic medicines focus continues to be chronic ailments customer i.e. 6.43 lakhs against 6.42 against branded
Slide 16: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy 15 zotahealthcare.com
Slide 17: Davaindia - COCO Stores
Davaindia- COCO Stores 16 zotahealthcare.com
Slide 18: Operational FOFO Stores
Operational FOFO Stores 537 States Arunachal Pradesh Assam No. of Stores 1 7 OPERATIONAL FOFO STORES AS Bihar 16 ON 30.06.2022 Chhattisgarh 2 Delhi 32 Goa 1 Gujarat 55 Haryana 30 Himachal Pradesh 1 Jammu And Kashmir 3 Jharkhand 7 Karnataka 10 Kerala 17 Madhya Pradesh 68 Maharashtra 52 Meghalaya 1 Od
Slide 19: Operational COCO Stores
Operational COCO Stores 36 State Gujarat Haryana No. of Stores 12 2 OPERATIONAL COCO STORES Maharashtra 11 AS ON 30.06.2022 Rajasthan 4 Delhi 3 Madhya Pradesh 1 Uttar Pradesh 3 Legend Company Owned Company Operated (COCO) Stores 18 Operated by wholly-owned subsidiary zotahealthcare.com Davaindia Hea
Slide 20: Management Commentary
Management Commentary Commenting on Q1FY23 financial performance and operational highlights, Management Team of Zota Health Care said, “Zota Health Care’s Q1FY23 performance was subdued due to lower dispatches on the Domestic sales front. During the quarter, the Company shifted to a new third-party
Slide 21: Industry Snapshot & Business Strategy
Industry Snapshot & Business Strategy zotahealthcare.com
Slide 22: Retail Generic Medicine Landscape in India
Retail Generic Medicine Landscape in India To achieve the objective of making available quality generic medicines at affordable prices to all, ‘Jan Aushadhi Scheme’ was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India across the county. The sche
Slide 23: Impact of PMBJP
Impact of PMBJP In the financial year (2019-20), PMBJP has achieved sales of ₹258 crores (at MRP), up to 30-11-2019. This has led to savings of approximately ₹1,800 crores of the common citizens of the country. Growth in number of stores Growth in turnover Product basket Price of Janaushadhi medicin
Slide 24: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 4 pillars to drive Branded and generic mix of Indian healthcare pharma market (%) Overall India Urban India Rural India 4 As of healthcare 8 6 15 1 Accessibility 2 Affordability 3 Awarness 4 Aliments 92 94 85 • Setting up of new • Higher per capita • Rising li
Slide 25: Financial Summary
Financial Summary zotahealthcare.com
Slide 26: Profit & Loss Statement
Profit & Loss Statement Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Income from Operations 5,646.3 6,473.3 7,158.0 7,785.2 8,562.9 9,511.3 10,684.12 13,153.33 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 125.66 164.56 Total Income 5,647.8 6,481.0 7,163.6 7,937.0 8,717.4 9,662.6 10,
Slide 27: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2456.03 2,516.0 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,181.2 6,621.4 Non-current liabilities 521.3 5
Slide 28: Thank You
Thank You Contact Information Mr. Himanshu Zota / Mr. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com